Status:
COMPLETED
Effect of Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation(TMS) on Brain Derived Neurotrophic Factor (BDNF) in Depressed Patients.
Lead Sponsor:
Queen's University
Conditions:
Depression
Eligibility:
All Genders
18-65 years
Brief Summary
To investigate the change in brain derived neurotrophic factor (BDNF) between pre and post treatment for patients with depression with either ECT or TMS.
Eligibility Criteria
Inclusion
- MDD or bipolar disorder;
- current depressive episode, ham-d17\>17 and ymrs\<8;
- recommended to receive ECT or TMS as part of clinical care;
- male/female;
- age 18-65;
- inpatient or outpatient;
- comorbid dysthymic disorder, gad, or social anxiety will be included;
- able to give written consent and agree.
Exclusion
- current manic, hypomanic, or mixed episode, ymrs\>7;
- current schizophrenia, anorexia, bulimia, substance dependence (current within past 6 months excluding caffeine and nicotine);
- TMS or ECT in the last 3 months;
- any other primary diagnosis;
- uncontrolled medical illness;
- epilepsy or severe personality disorder at the discretion of the investigators;
- 3 weeks prior to first blood test, antidepressants, mood stabilizers, antipsychotics can not be added or increased;
- pregnant women or women of childbearing potential not willing to use appropriate contraception, nursing women;
- known intolerance or lack of response to treatment receiving as judged by the investigator;
- medical conditions that would affect serum levels of BDNF;
- involvement in planning and conduct of the study.
Key Trial Info
Start Date :
November 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00630123
Start Date
November 1 2006
End Date
December 1 2012
Last Update
December 16 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Providence Care Mental Health Services
Kingston, Ontario, Canada, K7L4X3